StreetInsider.com News Articles

Form 6-K Quantum Biopharma Ltd. For: Sep 17

Thu, 17 Sep 2026 15:13:00 -0400

si-local-file:///var/storage/secattach/20260917/27075463.html

Form 6-K Quantum Biopharma Ltd. For: Sep 17

Thu, 17 Sep 2026 08:00:00 -0400

si-local-file:///var/storage/secattach/20260917/27072951.html

Rodman & Renshaw Initiates Analyst Coverage on Quantum BioPharma with a BUY Rating and US$8 Price Target

Thu, 17 Sep 2026 08:00:00 -0400

TORONTO, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development, today announces Rodman & Renshaw has initiated coverage of Quantum BioPharma with a BUY rating and a US$8 price target. The lead analyst of this report is Michael G. King Jr., Director of Research, Senior Biotechnology Analyst at Rodman & Renshaw. This coverage

Rodman & Renshaw Initiates Analyst Coverage on Quantum BioPharma with a BUY Rating and US$8 Price Target

Thu, 17 Sep 2026 08:00:00 -0400

Rodman & Renshaw Initiates Analyst Coverage on Quantum BioPharma with a BUY Rating and US$8 Price Target

Thu, 17 Sep 2026 08:00:00 -0400

Rodman & Renshaw Initiates Analyst Coverage on Quantum BioPharma with a BUY Rating and US$8 Price Target

Thu, 17 Sep 2026 08:00:00 -0400

Rodman & Renshaw Initiates Analyst Coverage on Quantum BioPharma with a BUY Rating and US$8 Price Target

Thu, 17 Sep 2026 08:00:00 -0400

Rodman & Renshaw Initiates Analyst Coverage on Quantum BioPharma with a BUY Rating and US$8 Price Target

Thu, 17 Sep 2026 08:00:00 -0400

Rodman & Renshaw Initiates Analyst Coverage on Quantum BioPharma with a BUY Rating and US$8 Price Target

Thu, 17 Sep 2026 08:00:00 -0400

Rodman & Renshaw Initiates Analyst Coverage on Quantum BioPharma with a BUY Rating and US$8 Price Target

Thu, 17 Sep 2026 08:00:00 -0400

Quantum BioPharma to Attend the ArcStone-Kingswood Growth Summit 2026 in Toronto

Tue, 15 Sep 2026 08:00:00 -0400

TORONTO, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (FSE: 0K91) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development, announces is pleased to announce its participation in the upcoming 3rd Annual ArcStone-Kingswood Growth Summit in Toronto, taking place on September 16, 2026, at the Sheraton Center Toronto Hotel. Anthony Durkacz, Co-founder and Executive Co-chairman of the board of Quantum BioPharma, will be

Quantum BioPharma to Attend the ArcStone-Kingswood Growth Summit 2026 in Toronto

Tue, 15 Sep 2026 08:00:00 -0400

Form 6-K Quantum Biopharma Ltd. For: Sep 15

Tue, 15 Sep 2026 08:00:00 -0400

si-local-file:///var/storage/secattach/20260915/27061384.html

NetworkNewsAudio Announces Audio Press Release (APR) Discussing FDA Clearance for Trial of First-in-Class Treatment Creating ‘Rare Moment’ in MS Research

Mon, 14 Sep 2026 08:30:00 -0400

AUSTIN, Texas, Sept. 14, 2026 (GLOBE NEWSWIRE) -- via IBN – NetworkNewsAudio announces the Audio Press Release (APR) titled “A Micro-Cap Biotech Just Cleared a Milestone Most Never Reach,” featuring Quantum BioPharma Ltd. (NASDAQ: QNTM).

To hear the NetworkNewsAudio version, visit https://ibn.fm/NYGrX

To read the original editorial, visit: https://ibn.fm/w10cb

Even large, well-funded competitors are still searching for something better. Several major pharmaceutical companies have advanced new [multiple sclerosis] MS candidates through late-stage trials in recent years only to see mixed or disappointing results, including recent failures in the broader

NetworkNewsAudio Announces Audio Press Release (APR) Discussing FDA Clearance for Trial of First-in-Class Treatment Creating ‘Rare Moment’ in MS Research

Mon, 14 Sep 2026 08:30:00 -0400

To hear the NetworkNewsAudio version, visit https://ibn.fm/NYGrX

To read the original editorial, visit: https://ibn.fm/w10cb

Quantum BioPharma gets FDA clearance for MS drug phase 2 trial

Fri, 11 Sep 2026 08:31:00 -0400

Quantum BioPharma Ltd. (NASDAQ: QNTM) has received clearance from the U.S. Food and Drug Administration to begin a phase 2 clinical trial of Lucid-MS, a drug candidate targeting multiple sclerosis, according to a statement from the company.

Lucid-MS is described as a patented, first-in-class compound designed to protect and potentially rebuild the myelin sheath, the protective coating around nerve fibers that deteriorates in MS patients. The drug's mechanism differs from existing MS treatments, which aim to slow immune system activity rather than address myelin directly.

Current MS therapies can slow disease progression but do not halt it or restore lost function. Approximately

Quantum BioPharma gets FDA clearance for MS drug phase 2 trial

Fri, 11 Sep 2026 08:31:00 -0400

Current MS therapies can slow disease progression but do not halt it or restore lost function. Approximately

Quantum BioPharma Ltd. (NASDAQ: QNTM) Filling Key Gap in MS Treatment, Cleared by FDA to Launch Historic Trials

Fri, 11 Sep 2026 08:30:00 -0400

NEW YORK, Sept. 11, 2026 (GLOBE NEWSWIRE) -- via BioMedWire — Quantum BioPharma Ltd. (NASDAQ: QNTM) today announces its placement in an editorial published by BioMedWire (BMW), one of 75+ brands within the Dynamic Brand Portfolio@IBN (InvestorBrandNetwork), a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community.

To view the full publication, “Historic First in MS Treatment Could Reshape a Multibillion-Dollar Therapeutics Market,” please visit: https://ibn.fm/HOCTP

Quantum BioPharma Ltd. (NASDAQ: QNTM) Filling Key Gap in MS Treatment, Cleared by FDA to Launch Historic Trials

Fri, 11 Sep 2026 08:30:00 -0400

To view the full publication, “Historic First in MS Treatment Could Reshape a Multibillion-Dollar Therapeutics Market,” please visit: https://ibn.fm/HOCTP

Quantum BioPharma Ltd. (NASDAQ: QNTM) Filling Key Gap in MS Treatment, Cleared by FDA to Launch Historic Trials

Fri, 11 Sep 2026 08:30:00 -0400

To view the full publication, “Historic First in MS Treatment Could Reshape a Multibillion-Dollar Therapeutics Market,” please visit:

Quantum BioPharma Ltd. (NASDAQ: QNTM) Filling Key Gap in MS Treatment, Cleared by FDA to Launch Historic Trials

Fri, 11 Sep 2026 08:30:00 -0400

NEW YORK, Sept. 11, 2026 (GLOBE NEWSWIRE) -- via BioMedWire — Quantum BioPharma Ltd. (NASDAQ: QNTM) today announces its placement in an editorial published by BioMedWire (BMW), one of 75+ brands within the Dynamic Brand Portfolio@IBN (InvestorBrandNetwork), a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community.

To view the full publication, “Historic First in MS Treatment Could Reshape a Multibillion-Dollar Therapeutics Market,” please visit:

Quantum BioPharma Ltd. (NASDAQ: QNTM) Filling Key Gap in MS Treatment, Cleared by FDA to Launch Historic Trials

Fri, 11 Sep 2026 08:30:00 -0400

NEW YORK, Sept. 11, 2026 (GLOBE NEWSWIRE) -- via BioMedWire — Quantum BioPharma Ltd. (NASDAQ: QNTM) today announces its placement in an editorial published by BioMedWire (BMW), one of 75+ brands within the Dynamic Brand Portfolio@IBN (InvestorBrandNetwork), a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community.

To view the full publication, “Historic First in MS Treatment Could Reshape a Multibillion-Dollar Therapeutics Market,” please visit:

Quantum BioPharma Ltd. (NASDAQ: QNTM) Filling Key Gap in MS Treatment, Cleared by FDA to Launch Historic Trials

Fri, 11 Sep 2026 08:30:00 -0400

NEW YORK, Sept. 11, 2026 (GLOBE NEWSWIRE) -- via BioMedWire — Quantum BioPharma Ltd. (NASDAQ: QNTM) today announces its placement in an editorial published by BioMedWire (BMW), one of 75+ brands within the Dynamic Brand Portfolio@IBN (InvestorBrandNetwork), a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community.

To view the full publication, “Historic First in MS Treatment Could Reshape a Multibillion-Dollar Therapeutics Market,” please visit:

Historic First in MS Treatment Could Reshape a Multibillion-Dollar Therapeutics Market

Thu, 10 Sep 2026 08:30:00 -0400

AUSTIN, Texas, Sept. 10, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Today's multiple sclerosis treatments can slow down disease progression, but none of them halt it outright, and none give back the function patients have already lost. Close to a million people in the United States, and nearly 2.9 million worldwide, live with that reality, watching a condition that steadily chips away at mobility, eyesight and basic physical control. That gap in treatment options just picked up a serious new contender. Quantum BioPharma Ltd. (NASDAQ: QNTM) (profile) has

Historic First in MS Treatment Could Reshape a Multibillion-Dollar Therapeutics Market

Thu, 10 Sep 2026 08:30:00 -0400

AUSTIN, Texas, Sept. 10, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Today's multiple sclerosis treatments can slow down disease progression, but none of them halt it outright, and none give back the function patients have already lost. Close to a million people in the United States, and nearly 2.9 million worldwide, live with that reality, watching a condition that steadily chips away at mobility, eyesight and basic physical control. That gap in treatment options just picked up a serious new contender. Quantum BioPharma Ltd. (NASDAQ: QNTM) (profile) has